国家医保局：按照“稳临床、保质量、防围标、反内卷”原则持续推进集采改革

Core Viewpoint - The Chinese government is actively promoting the "14th Five-Year Plan" with a focus on high-quality healthcare reforms, particularly through centralized drug procurement to lower drug prices and improve the healthcare ecosystem [1][2]. Group 1: Drug Procurement Reforms - The National Medical Insurance Administration has implemented 10 batches of centralized drug procurement since 2018, covering 435 types of drugs, which has effectively reduced drug prices and improved accessibility for the public [1][2]. - The 11th batch of centralized procurement has been initiated, optimizing procurement rules to ensure quality and prevent market manipulation, including a new pricing anchor that does not solely rely on the lowest bid [2]. Group 2: Credit Evaluation System - A credit evaluation system has been established to address issues like medical kickbacks and inflated drug prices, with 735 companies identified as untrustworthy by the end of 2024, affecting their procurement qualifications [2]. - The implementation of the credit evaluation system is shifting the market approach for pharmaceutical companies from high-price strategies to quality-focused management [2]. Group 3: Insurance Coverage and Financials - During the "14th Five-Year Plan," the basic medical insurance coverage rate has stabilized at around 95%, with an expected 1.327 billion insured individuals by 2024 [3]. - The cumulative expenditure of the medical insurance fund has reached 12.13 trillion yuan, with an annual growth rate of 9.1%, and a cumulative balance of 3.86 trillion yuan by the end of 2024 [3].